EKF has continued its recent pattern of raising and beating estimates by delivering results slightly ahead of expectations, despite some revenue headwinds after the ending of a large Saudi tender in FY17. Significant shareholder value was created during the year (EKF was an N+1 Singer Best Idea for 2018), delivering a total return of 27% including the 5.5p/share in specie distribution of shares in Renalytix AI, which IPO’d on AIM in November. The outlook remains positive, supported by new produc ....
